Patents by Inventor David R. Hathaway

David R. Hathaway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CARDIAC ARRHYTHMIAS
    Publication number: 20140200183
    Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
    Type: Application
    Filed: March 21, 2014
    Publication date: July 17, 2014
    Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLC
    Inventors: David R. HATHAWAY, Alain D. BARON
  • Treatment of cardiac arrhythmias
    Patent number: 8389473
    Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: March 5, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: David R. Hathaway, Alain D. Baron
  • PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
    Publication number: 20110178014
    Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
    Type: Application
    Filed: March 30, 2010
    Publication date: July 21, 2011
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: David R. Hathaway, Alain D. Baron
  • Methods and compositions for treating polycystic ovary syndrome
    Patent number: 7960341
    Abstract: The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: June 14, 2011
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: David R. Hathaway, Nigel Robert Arnold Beeley, Kathryn Susan Prickett, Andrew A. Young
  • Compositions and methods for treating peripheral vascular disease
    Patent number: 7888314
    Abstract: The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: February 15, 2011
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: David R. Hathaway, Thomas R. Coolidge
  • Treatment of cardiac arrhythmias with GLP-1 receptor ligands
    Patent number: 7790681
    Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: September 7, 2010
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: David R. Hathaway, Alain D. Baron
  • Compositions for the Treatment and Prevention of Nephropathy
    Publication number: 20090203603
    Abstract: Compositions and methods for the prevention and treatment of nephropathy, including hypertensive and diabetic nephropathy, and nephropathy associated with insulin resistance and metabolic syndrome are described. Compositions of the invention include a compound that binds to a receptor for the glucagon like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an analog (including an agonist analog), derivative, or variant of any of them.
    Type: Application
    Filed: December 18, 2008
    Publication date: August 13, 2009
    Applicant: AMYLIN PHARMACEUTICALS, INC.
    Inventors: Alain Baron, David R. Hathaway, Mahesh Mistry, Richard J. Roman
  • Compositions and methods for treating peripheral vascular disease
    Patent number: 7259136
    Abstract: The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: August 21, 2007
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: David R. Hathaway, Thomas R. Coolidge
  • Methods and compositions for treating polycystic ovary syndrome
    Patent number: 7105489
    Abstract: The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1) to subjects suffering therefrom.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: September 12, 2006
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventor: David R. Hathaway
  • Methods and compositions for treating polycystic ovary syndrome
    Patent number: 7105490
    Abstract: The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: September 12, 2006
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Andrew A. Young, David R. Hathaway
  • Methods and compositions for treating polycystic ovary syndrome
    Publication number: 20040266678
    Abstract: The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.
    Type: Application
    Filed: July 30, 2003
    Publication date: December 30, 2004
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Andrew A. Young, David R. Hathaway
  • Prevention and treatment of cardiac arrhythmias
    Publication number: 20040266683
    Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
    Type: Application
    Filed: December 17, 2003
    Publication date: December 30, 2004
    Inventors: David R. Hathaway, Alain D. Baron
  • Compositions for the treatment and prevention of nephropathy
    Publication number: 20040209803
    Abstract: Compositions and methods for the prevention and treatment of nephropathy, including hypertensive and diabetic nephropathy, and nephropathy associated with insulin resistance and metabolic syndrome are described. Compositions of the invention include a compound that binds to a receptor for the glucagon like peptide-1, an incretin, a glucagon-like peptide-1 (GLP1), an exendin, or an analog (including an agonist analog), derivative, or variant of any of them.
    Type: Application
    Filed: December 19, 2003
    Publication date: October 21, 2004
    Inventors: Alain Baron, David R. Hathaway, Mahesh Mistry, Richard J. Roman
  • Methods and compositions for treating polycystic ovary syndrome
    Publication number: 20040029784
    Abstract: The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1) to subjects suffering therefrom.
    Type: Application
    Filed: December 11, 2002
    Publication date: February 12, 2004
    Inventor: David R. Hathaway
  • Compositions and methods for treating peripheral vascular disease
    Publication number: 20030073626
    Abstract: The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom.
    Type: Application
    Filed: March 5, 2002
    Publication date: April 17, 2003
    Inventors: David R. Hathaway, Thomas R. Coolidge
  • Method and apparatus for intravascular drug delivery
    Patent number: 5306250
    Abstract: A drug delivery catheter assembly, including an expandable, porous outer membrane that is insertable into a blood vessel and positioned adjacent a stenotic atherosclerotic lesion on the interior wall of the blood vessel. The membrane is expanded into contact with the lesion, either mechanically or hydraulically. After the membrane is expanded, a drug-containing liquid is caused to flow into the membrane and through the pores in the membrane into contact with the lesion.
    Type: Grant
    Filed: April 2, 1992
    Date of Patent: April 26, 1994
    Assignee: Indiana University Foundation
    Inventors: Keith L. March, David R. Hathaway, Robert L. Wilensky
  • Method for delivery of smooth muscle cell inhibitors
    Patent number: 5171217
    Abstract: A method and composition for delivering a drug to an affected intramural site for sustained release in conjunction with or following balloon catheter procedures, such as angioplasty. The drug, carried by microparticles of a physiologically-compatible, biodegradable polymer is injected under directed pressure into the wall of a body vessel in the region of the affected site.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: December 15, 1992
    Assignee: Indiana University Foundation
    Inventors: Keith L. March, David R. Hathaway, Robert L. Wilensky
  • Method for preventing restenosis following reconfiguration of body vessels
    Patent number: 5116864
    Abstract: Restenosis following vascular recanalization is prevented by administering a photoactivatable psoralen and, in conjunction with recanalization, delivering ultraviolet radiation to the region of said recanalization.
    Type: Grant
    Filed: April 9, 1991
    Date of Patent: May 26, 1992
    Assignee: Indiana University Foundation
    Inventors: Keith L. March, David R. Hathaway, Robert L. Wilensky, Brian L. Patton